ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stirling, R.
Right arrow Articles by Chung, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stirling, R.
Right arrow Articles by Chung, K.
Eur Respir J 2000; 16: 1158-1174
Copyright © ERS Journals Ltd 2000

Original Articles

New immunological approaches and cytokine targets in asthma and allergy

RG Stirling and KF Chung

The aims of current asthma treatment are to suppress airway inflammation and control symptoms, and corticosteroids maintain a commanding position in this role. Steroids effectively suppress inflammation in the majority of patients but have little impact on the natural history of this disease. In severe asthmatics, corticosteroids may have relatively less beneficial effects. Recent advances in understanding the inflammatory and immunological mechanisms of asthma have indicated many potential therapeutic avenues that may prevent or reverse abnormalities that underlie asthma. As the roles of effector cells, and of signalling and adhesion molecules are better understood, the opportunities to inhibit or prevent the inflammatory cascade have increased. In addition, there have been advances in the synthesis of proteins, monoclonal antibodies and new small molecule chemical entities, which may provide valuable flexibility in the therapeutic approach to asthma. The novel immunological approaches include the prevention of T-cell activation, attempts to influence the balance of T-helper cell (Th) populations to inhibit or prevent Th2-derived cytokine expression, and the inhibition or blockade of the downstream actions of these cytokines such as effects on immunoglobulin-E and eosinophils. These approaches provide broad as well as highly specific targeting, and also prospects for prevention and reversal of immunological and inflammatory abnormalities associated with asthma. Hopefully, the development of effective antiasthma agents with effects beyond those provided by current therapies coupled with lesser side-effects will further address the unmet needs of asthma.


This article has been cited by other articles:


Home page
 Psychosom. Med.Home page
M. J. Griffin and E. Chen
Perceived Control and Immune and Pulmonary Outcomes in Children With Asthma
Psychosom Med, May 1, 2006; 68(3): 493 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Y. Amrani, O. Tliba, D. Choubey, C.-D. Huang, V. P. Krymskaya, A. Eszterhas, A. L. Lazaar, and R. A. Panettieri Jr.
IFN-gamma inhibits human airway smooth muscle cell proliferation by modulating the E2F-1/Rb pathway
Am J Physiol Lung Cell Mol Physiol, June 1, 2003; 284(6): L1063 - L1071.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. E. Taylor, T. Moore, and P. Paisley
The time has finally arrived: use of intravital microscopy in the airway circulation
Am J Physiol Lung Cell Mol Physiol, May 1, 2002; 282(5): L957 - L958.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. T. SEAH, P. S. GAO, J. M. HOPKIN, and G. A. W. ROOK
Interleukin-4 and Its Alternatively Spliced Variant (IL-4delta 2) in Patients with Atopic Asthma
Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 1016 - 1018.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.